|Toxiciy Grade:||5||City/State/Province:||St. Louis, MO|
|Treatments:||Chemotherapy, Radiation, Surgery||Hospital:||Washington University Medical Center|
Patients: This Phase II study involved 88 patients diagnosed with non-small-cell lung cancer (resected stage II or IIIA) Fifty-seven patients were men, and thirty-one were women. Forty-nine patients (56%) were younger than 60 years old.
Treatment: The treatment involved surgery and thoracic radiotherapy and chemotherapy with two drugs: paclitaxel and carboplatin.
Toxicity: There was one septic death. Grade 3-4 toxicities included granulocytopenia, leukopenia, thrombocytopenia, esophagitis, respiratory, and neurologic toxicity.
Results: The median overall survival was 56.3 months.
Support: Some authors have served as consultants, advisors or grant recipients to various pharmaceutical companies.
Correspondence: Jeffrey D. Bradley, M.D.